The Latest Breaking News from Arcturus rapeutics

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022

Upgrades

Benzinga · Nov 10, 2022

CSL paying $312m to license mRNA vax tech

CSL Seqirus is paying $A312 million up-front to license next-generation mRNA technology from a small US company, Arcturus Therapeutics.

AAP · Nov 2, 2022

Arcturus Therapeutics's Return On Capital Employed Overview

Benzinga Pro data, Arcturus Therapeutics (NASDAQ:ARCT) reported Q1 sales of $5.24 million. Earnings fell to a loss of $51.17 million, resulting in a 32.35% decrease from last quarter.

Benzinga · Jun 6, 2022

Arcturus Therapeutics's Earnings Outlook

Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Arcturus Therapeutics will report an earnings per share (EPS) of $-1.72.

Benzinga · Feb 25, 2022